Entries |
Document | Title | Date |
20080207758 | Rhein Conjugates, Preparation Method Thereof and Their Uses in Producing Medicines for Treating Diabetic Nephrosis, Intestinal Adhesion and Osteoarthritis - The conjugates of present invention are formed by the combination of rhein or their analogues with the organic bases or amino acids in molecular force between them. The methods for preparing the conjugates and their uses for manufacturing medicines in the treatment of diabetic nephrosis, recovery of gastrointestinal function and prevention of intestinal adhesion, as well as treatment of osteoarthritis, rheumatic arthritis and rheumatoid arthritis are also described. Rhein or their analogues as the left part of general formula (I) is selected from (1) the compounds of rhein or their analogues, in which one or two substituents of R2˜R3 and R6˜R7 are COOH at least two substituents of R1˜8 are —H; or (2) the rhein-containing extract derived from plants. In general formula (I), M represents nitrogen-containing organic bases or basic amino acids. | 08-28-2008 |
20080242729 | Rxr Antagonists in the Treatment of Inflammatory Diseases - Retinoids with retinoid antagonistic activities, especially Retinoid X Receptor antagonists called RXR antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable esters and amides thereof, have been found to be efficacious in the treatment of inflammatory diseases of the skin and mucous membranes, and of other tissues and organs for example by topical or oral administration of RXR antagonists. | 10-02-2008 |
20080300312 | Treatment of cancer with specific RXR agonists - A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose. | 12-04-2008 |
20090012171 | Novel Compounds, Their Preparation and Use - Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype. | 01-08-2009 |
20090012172 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among the salts of 18β-glycyrrhetinic acid and derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 01-08-2009 |
20090023811 | Biphenyl compound selective agonists of gamma RAR receptors - Biphenyl compounds having the formula (I): | 01-22-2009 |
20090099262 | Methods and Compositions for the Management of Soil Borne Fungal Diseases - Improved methods and compositions for protecting plants or seeds from soil-borne fungal diseases. The composition may include a triterpenoid isolated from | 04-16-2009 |
20090124697 | Inhalation formulations of treprostinil - The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof. | 05-14-2009 |
20090182052 | TASTE-MASKED DOCUSATE COMPOSITIONS - A taste-masked liquid composition of docusate includes a docusate salt, povidone, a polyether, and water. Additional ingredients in the composition may include thickeners, sweeteners, flavorants, polyols, preservatives, chelating agents and pH adjusters. Such compositions may be used as taste-masked oral compositions of docusate, and may provide therapeutic effects such as stool-softening. | 07-16-2009 |
20090264531 | SULINDAC FORMULATIONS IN A BIODEGRADABLE MATERIAL - Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 10-22-2009 |
20090281187 | ANTI-ALLERGIC AGENT - The inventors have found that vitamin K3 and vitamin K5 which may be used in pharmaceuticals and foods or ACNQ, DHNA, or the like which can stimulate the growth of bifidobacteria can inhibit degranulation of basophil-like cells, exhibit a potent degranulation-inhibiting effect, and are useful anti-allergic agents or foods. The present invention provides an anti-allergic agent containing, as an active ingredient, one or more species selected from among 2-amino-3-carboxy-1,4-naphthoquinone, 1,4-dihydroxy-2-naphthoic acid, 1,4-naphthoquinone, 4-amino-2-methyl-1-naphthol, 2-methyl-1,4-naphthoquinone, 2-amino-3-chloro-1,4-naphthoquinone, and a salt thereof. | 11-12-2009 |
20090281188 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 11-12-2009 |
20090281189 | TREPROSTINIL FORMULATION - There is provided a stable monohydrate form of treprostinil and pharmaceutical formulation comprising the same, method of making and using the same. | 11-12-2009 |
20090312425 | PROCESS FOR PRODUCING 1,4-DIHYDROXY-2-NAPHTHOIC ACID - A composition containing 1,4-dihydroxy-2-naphthoic acid at a high concentration is obtained by intracellularly and extracellularly producing 1,4-dihydroxy-2-naphthoic acid using a bacterium belonging to the genus | 12-17-2009 |
20090318558 | SOLVENT SYSTEM OF HARDLY SOLUBLE DRUG WITH IMPROVED DISSOLUTION RATE - The present invention relates to a solvent system with improved disintegration degree and dissolution ratio of a hardly soluble drug by highly concentrating the drug through partial ionization, and by establishing optimal conditions for enhancing bioavailability of the drug, such as the co-relation between the acid drug and the accompanied components, ionization degree of a solvent system, use of an appropriate cation acceptor, water content, selection of optimal mixing ratio of the respective components and use of specific surfactants, and to a pharmaceutical preparation comprising the same. The solvent system of the invention has advantages in that it can enhance bioavailability by improving the disintegration degree and dissolution ratio of a hardly soluble drug and also provide a capsule with a sufficiently small volume to permit easy swallowing. | 12-24-2009 |
20090326073 | PROTECTION OF NORMAL CELLS - The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms. | 12-31-2009 |
20100056634 | NOVEL COMPOSITIONS - The present invention relates to novel composition for the treatment, co-treatment or prevention of inflammatory disorders comprising an effective amount of carnosic acid 12-methylether. | 03-04-2010 |
20100069495 | Topical application of adapalene for the long-term treatment of acne vulgaris - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 03-18-2010 |
20100076083 | Treprostinil administration using a metered dose inhaler - Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil. | 03-25-2010 |
20100087539 | N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT - The invention relates to the field of organic chemistry and medicine, in particular to virology. More specifically the invention relates to a novel chemical compound N′-{N-[3-oxo-lupan-28-oyl]-9-aminononanoyl}-3-amino-3-phenylpropionic acid of formula 1 and to pharmaceutically acceptable salts and prodrug forms thereof exhibiting an anti-viral (anti-HIV) and immunostimulating activity. A method for producing the compound of formula 1 and the use thereof for the manufacture of a medicinal agent exhibiting an anti-viral (anti-HIV) and immunostimulating activity is also disclosed. | 04-08-2010 |
20100130613 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF CD1d OR IL-10 - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of CD1d or IL-10 in an inflammatory acneic lesion. | 05-27-2010 |
20100130614 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF IL-1ra - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of IL-1ra by the cells of acneic epidermis. | 05-27-2010 |
20100144883 | TOPICALLY APPLICABLE COMPOSITIONS FOR THE TREATMENT OF KERATINIZATION DISORDERS - Topical compositions containing from 0.01% to 0.09% by weight of adapalene or salts thereof are useful for the treatment or prevention of keratinization disorders, particularly acne, and additionally contain at least one gelling agent selected from among carbomers, polysaccharides, cellulose and its derivatives, copolymers of acrylate and of alkyl acrylate, copolymers of acrylamide and of sodium acrylamido-2-methylpropanesulfonate, and xanthan gum. | 06-10-2010 |
20100152294 | Assays For Detecting Inhibitors Of Binding Between COX-2 And PDZ Proteins - The invention provides an assay for determining whether a test agent is a COX modulator. In general terms, the assay includes: determining whether a test agent modulates binding of a PDZ-containing polypeptide to a COX PL-containing polypeptide. The PDZ-containing polypeptide may contain the PDZ domain of PDZ domain of MAGI1, TIP-1, MAST2, PSD95, or SHANK. The assays may be done in a cell-free environment or in a cellular environment, particularly using a neuronal cell. The invention finds use in a variety of therapeutic applications, including for identifying agents for use in treating cancer, pain, inflammation and neuronal conditions caused by acute insult, e.g., stroke. | 06-17-2010 |
20100160439 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE - Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: | 06-24-2010 |
20100168241 | TREATMENT OF ACNE DISEASE STATES, NOTABLY ACNE VULGARIS - Acne disease states, notably acne vulgaris, are treated with naphthoic acid compounds and particularly adapalene in association/combination with light therapy. | 07-01-2010 |
20100273882 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 10-28-2010 |
20100273883 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof - Novel ligand compounds having the structural formula (I): | 10-28-2010 |
20100280121 | PRODUCTION OF ADAPALENE GELS - A method for producing an adapalene aqueous gel on an industrial scale including formulating a gelling medium A by mixing water and propylene glycol and adding a gelling agent thereto; formulating an adapalene medium B by dispersing adapalene in water, in the presence of a surfactant; next adding the adapalene medium B to the gelling medium A; and adjusting the pH to about 4.7-5.3. | 11-04-2010 |
20100286277 | METHOD TO ENHANCE AQUEOUS SOLUBILITY OF POORLY SOLUBLE ACTIVES - A method to enhance solubility of an active compound comprises combining an active compound, having an aqueous solubility that is less than or equal to about 10 mg/mL, and an amount of methoxypolyethylene glycol that is sufficient to increase the aqueous solubility of the active compound. Enhancement of aqueous solubility for this combination may be significantly greater than that of an active compound in combination with an equivalent amount of polyethylene glycol. Particularly enhanced solubility is shown where a small amount of water is also included. The invention may be used in a wide variety of applications, such as for pharmaceutical, agricultural, antimicrobial, and personal care products. | 11-11-2010 |
20110003894 | DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS - Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. | 01-06-2011 |
20110009491 | PROCESS FOR PRODUCING 1,4-DIHYDROXY-2-NAPHTHOIC ACID - A composition containing 1,4-dihydroxy-2-naphthoic acid at a high concentration is obtained by intracellularly and extracellularly producing 1,4-dihydroxy-2-naphthoic acid using a bacterium belonging to the genus | 01-13-2011 |
20110054032 | DIOXOANTHRACENE SULPHONATE DERIVATIVES - Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R | 03-03-2011 |
20110092598 | Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof - An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API. | 04-21-2011 |
20110092599 | Use of Treprostinil to treat neuropathic diabetic foot ulcers - The present invention describes novel methods for using 9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F | 04-21-2011 |
20110130461 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 06-02-2011 |
20110152372 | ANHYDROUS PETROLEUM JELLY/ELASTOMER-FREE DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND AND A RETINOID - Novel dermatological depigmentation compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound and a retinoid, formulated as anhydrous compositions free of petroleum jelly and free of elastomer. | 06-23-2011 |
20110257269 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES - The present invention relates to a preventive and/or a therapeutic agent for inflammatory bowel diseases containing a fermentation product of a propionic acid bacterium as an active ingredient. | 10-20-2011 |
20110281948 | COSMETIC AND PHARMACEUTICAL FORMULATIONS OF CALIXARENE MOLECULES - The invention relates to the use of calixarenes for preventing or limiting the transfer of an actinide in the body from a site of skin contamination. | 11-17-2011 |
20110319491 | ANHYDROUS DEPIGMENTING COMPOSITIONS COMPRISING, WITHIN THE FATTY PHASE THEREOF, A SOLUBILIZED PHENOLIC COMPOUND AND A RETINOID - Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, within the fatty phase thereof, as pharmaceutical active agents, a dissolved phenolic compound and a retinoid. | 12-29-2011 |
20120004307 | ORAL TREATMENT OF DIGITAL ISCHEMIC LESIONS - Provided are methods of orally treating ischemic diseases and conditions, such as digital ulcers, associated with or caused by the ischemic diseases. | 01-05-2012 |
20120016031 | BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS - Biphenyl compounds having the formula (I): | 01-19-2012 |
20120059063 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 03-08-2012 |
20120122987 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) - Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation. | 05-17-2012 |
20120136059 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 05-31-2012 |
20120165410 | PRODUCTION OF ENCAPSULATED NANOPARTICLES AT HIGH VOLUME FRACTIONS - The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments. | 06-28-2012 |
20120184622 | COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS - The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis in a subject. | 07-19-2012 |
20120252897 | COMBINATION COMPOSITION COMPRISING BENZOYL PEROXIDE AND ADAPALENE - An aqueous gel composition of the present invention comprising about 0.1 to 0.3 wt % adapalene and about 2.5 to 5.0 wt % benzoyl peroxide, as active ingredients, wherein both the active ingredients are stabilized in hydrophilic gelling matrix of pH dependent gelling agent comprising crosslinked, acrylic acid-based polymer(s). | 10-04-2012 |
20120259017 | Use of Propionic Acid as an Antimicrobial - Propionic acid is used to curb the growth of | 10-11-2012 |
20120295979 | USE OF SULINDAC FOR PROTECTING RETINAL PIGMENT EPITHELIAL CELLS AGAINST OXIDATIVE STRESS - Compositions and methods described herein are based on the use of the drug sulindac, a non steroidal anti-inflammatory drug (NSAID), for protecting retinal pigment epithelial cells against oxidative stress which is a major component of macular degeneration. Described herein is a new use for sulindac. | 11-22-2012 |
20120295980 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS - This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula: | 11-22-2012 |
20120309833 | NOVEL BEXAROTENE ANALOGS - The present invention relates to analogs of bexarotene and methods of use thereof. | 12-06-2012 |
20130041035 | TOPICAL APPLICATION OF ADAPALENE FOR THE LONG-TERM TREATMENT OF ACNE VULGARIS - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 02-14-2013 |
20130046022 | GEL COMPOSITION FOR TREATMENT OF COMMON ACNE COMPRISING A COMBINATION OF BENZOYL PEROXIDE AND ADAPALENE AND/OR ADAPALENE SALT - Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C. | 02-21-2013 |
20130096200 | TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA - The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof. | 04-18-2013 |
20130131177 | USE OF A DERMATOLOGICAL COMPOSITION COMPRISING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE WHICH IS INTENDED FOR THE TREATMENT OF ACNE IN NON-CAUCASIAN POPULATION WITH DECREASE OF POST-INFLAMMATORY HYPERPIGMENTATION - A dermatological composition including a combination of Adapalene and benzoyl peroxide is described. The composition is intended for the treatment of acne in the non-Caucasian population with decreased post-inflammatory hyperpigmentation, keloid scarring and acne hyperpigmented macules and cystic lesions. | 05-23-2013 |
20130203850 | METHOD FOR TREATING SCARS WITH ADAPALENE 0.3% - A method is described for treating a scar with an effective amount of adapalene or salts thereof, which is administrated to the patient in need thereof. Optionally, the administered adapalene is in a quantity of 0.3% by weight relative to the total weight of the composition. | 08-08-2013 |
20130245123 | COSMETIC/DERMATOLOGICAL COMPOSITIONS COMPRISING NAPHTHOIC ACID COMPOUNDS AND POLYURETHANE POLYMERS - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 09-19-2013 |
20130253062 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 09-26-2013 |
20130261187 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS - This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula: | 10-03-2013 |
20130274340 | BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME - Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided. | 10-17-2013 |
20130317108 | DERMATOLOGICAL FOAMS OBTAINED FROM A GEL OR SUSPENSION CONTAINING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE - Intermediate compositions, and in particular gels and suspensions for foam compositions, are described that include adapalene and benzoyl peroxide in combination. Also described; is the dermatological use of such compositions. | 11-28-2013 |
20130338230 | DERMATOLOGICAL FOAMS OBTAINED FROM A GEL OR SUSPENSION CONTAINING ADAPALENE - Intermediate compositions and in particular gels and suspensions for a foam composition comprising adapalene are described. Also described, is the dermatological use of such compositions. | 12-19-2013 |
20140005270 | DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES | 01-02-2014 |
20140018429 | PROTECTION OF NORMAL CELLS - The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms. | 01-16-2014 |
20140018430 | NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS - The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells. | 01-16-2014 |
20140018431 | TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA - The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof. | 01-16-2014 |
20140031427 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 01-30-2014 |
20140142184 | TOPICAL DAPSONE AND DAPSONE/ADAPLENE COMPOSITIONS AND METHODS FOR USE THEREOF - Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder. | 05-22-2014 |
20140163107 | ANTIVIRAL COMPOSITIONS DIRECTED AGAINST THE INFLUENZA VIRUS NUCLEOPROTEIN - A pharmaceutical composition for treating viral infections by an influenza type A virus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein. A pharmaceutical composition for treating viral infections by an orthomyxovirus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of orthomyxoviruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein of the viruses. A compound acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and binding to the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses and a method for identifying such a compound having these properties are also described. | 06-12-2014 |
20140194520 | BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME - Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided. | 07-10-2014 |
20140213651 | Novel Use of Adapalene in Treating Cancer - A novel use of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid or a pharmaceutically acceptable salt or functional derivative thereof in treating a cancer, and in particular non-small cell lung cancer, is provided. | 07-31-2014 |
20140249232 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 09-04-2014 |
20140256818 | NANO-SUSPENSION PROCESS - Described herein is a process for preparing nano-suspensions, wherein the process comprises: providing an admixture of at least one active pharmaceutical compound, an aqueous dispersion medium, and milling media and applying thereto acoustic energy having a frequency of from about 10 hertz to 1000 hertz and which supplies a linear acceleration of from about 10 G′s to about 100 G′s (where “G” is the force of gravity) for a period sufficient to supply a nano-suspension having a D | 09-11-2014 |
20140275262 | SOLID FORMS OF TREPROSTINIL - There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the same | 09-18-2014 |
20140275263 | Microemulsion Topical Delivery Platform - Provided are pharmaceutical carriers suitable based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by | 09-18-2014 |
20140288179 | STABLE SOLUTIONS OF TREPROSTINIL - An improved method for administering treprostinil or a salt is described that allows for use of the diluted solution prior to administration for a longer period of time to avoid wasted medication. | 09-25-2014 |
20140296340 | COMBINATION/ASSOCIATION OF ADAPALENE AND BENXOYL PEROXIDE FOR TREATING ACNE LESIONS - Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO). | 10-02-2014 |
20140296341 | FORMULATIONS BASED ON SOLID DISPERSIONS - The present invention relates to formulations comprising a solid dispersion product of an active agent having at least one of a hydrogen bond donor moiety (e.g. ibuprofen, fenofibric acid or naproxen) and a proton donor moiety and a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graft copolymer, and to methods for preparing such formulations. | 10-02-2014 |
20140303252 | OSMOTIC DRUG DELIVERY SYSTEM - An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent. | 10-09-2014 |
20140329903 | TREATMENT OF NEURODEGENERATIVE DISEASES - The present disclosure relates to compounds to be used in a low dose in treatment of neurodegenerative diseases or disorders. It also relates to methods for treatment of a neurodegenerative diseases or disorders. | 11-06-2014 |
20140350110 | CO-CRYSTALS OF TRAMADOL AND NSAIDs - The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain. | 11-27-2014 |
20140350111 | METHODS FOR TREATMENT AND PROPHYLAXIS AGAINST HEMORRHOIDS - Methods for treatment of and prophylaxis against hemorrhoids are disclosed, including methods of treatment of and prophylaxis against hemorrhoids comprising administering naproxen to an individual. | 11-27-2014 |
20150011636 | METHOD FOR TREATMENT OF DISEASES WITH DIOXOANTHRACENE SULPHONATE DERIVATIVES - Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R | 01-08-2015 |
20150011637 | CRYSTAL FORM OF PROSTAGLANDIN ANALOGUE, AND PREPARATION METHOD AND USE THEREOF - Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9±0.2°, 6.5±0.2°, 12.6±0.2°, 13.1±0.2° and 20.6±0.2°. | 01-08-2015 |
20150031767 | FULVIC ACID AND ANTIBIOTIC COMBINATION FOR THE INHIBITION OR TREATMENT OF MULTI-DRUG RESISTANT BACTERIA - Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum lactamase (ESBL) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, | 01-29-2015 |
20150038585 | Treatment of Diseases by Concurrently Eliciting Remyelination Effects and Immunomodulatory Effects Using Selective RXR Agonists - The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system. | 02-05-2015 |
20150045440 | METHOD FOR THE TREATMENT OF ACNE USING PHARMACEUTICAL COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 02-12-2015 |
20150087709 | Novel Formulation of Naproxen - The present invention relates to methods for producing particles of naproxen using dry milling processes as well as compositions comprising naproxen, medicaments produced using naproxen in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of naproxen administered by way of said medicaments. | 03-26-2015 |
20150126608 | TREATMENT OF PREADOLESCENT MODERATE ACNE VULGARIS - A method of treating preadolescent acne is described. The method can include administering an effective amount of a pharmaceutical composition that includes a fixed combination of adapalene and benzol peroxide to a preadolescent patient in need thereof. | 05-07-2015 |
20150306232 | HYDROGELATORS COMPRISING D-AMINO ACIDS - Described herein are compounds comprising an oligopeptide and a non-steroidal antiinflammatory agent. The compounds self-assemble into supramolecular hydrogels and can be used as topical treatments for inflammatory conditions, such as osteoarthritis. Also described herein are oligopeptides compounds made from D-amino acid residues that form supramolecular hydrogels. The compounds may be functionalized with active agents, such as anticancer therapeutic agents, antiinflammatory agents, or imaging agents, therefore providing new mechanisms for delivery of active agents. | 10-29-2015 |
20150313857 | Novel Formulation of Naproxen - The present invention relates to methods for producing particles of naproxen using dry milling processes as well as compositions comprising naproxen, medicaments produced using naproxen in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of naproxen administered by way of said medicaments. | 11-05-2015 |
20150359760 | LIPOLYTIC METHODS - Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally. | 12-17-2015 |
20150376106 | PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN.RTM. - This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil. | 12-31-2015 |
20160074350 | Retinopathy Treatment - A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject. | 03-17-2016 |
20160101077 | Compositions and Methods for Treating Severe Pain - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 04-14-2016 |
20160113895 | Novel Use of Adapalene in Treating Esophageal Cancer and Gastrointestinal Stromal Tumor - A novel use of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid or a pharmaceutically acceptable salt or functional derivative thereof in treating a cancer, and in particular esophageal cancer and gastrointestinal stromal tumor, is provided. | 04-28-2016 |
20160143868 | TREPROSTINIL ADMINISTRATION BY INHALATION - Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil. | 05-26-2016 |
20160175319 | COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS | 06-23-2016 |
20160199327 | Solid Solution Compositions and Use in Chronic Inflammation | 07-14-2016 |
20180021347 | COMPOSITION FOR THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE | 01-25-2018 |